Abstract 104P
Background
Bladder-sparing treatment has emerged as an alternative choice for patients who are concerned about the life quality after radical cystectomy (RC). The optimal strategy for bladder-sparing treatment such as trimodal therapy (TMT) showed similar effects with RC. Since neoadjuvant immunotherapy has illuminated considerable response in MIBC, we aim to study whether neoadjuvant chemotherapy plus immunotherapy can improve the bladder-sparing rate in MIBC patients.
Methods
30 planned patients with MIBC (T2-4a N0-1 M0) received cisplatin 70mg/m2 or carboplatin AUC 4.5 on day 1 every 3 weeks (Q3W) plus gemcitabine 1000 mg/m2 on the 1st and 8th day of each 21-day cycle x 4 cycles. Tislelizumab 200mg was administered on the 14th day of each 21-day cycle at the 3rd and 4th cycles. CT and cystoscopy imaging were carried out to evaluate disease progression. After the 4th treatment, radical cystectomy, partial cystectomy or TURBT were perform in accordance with the disease status. For continuous bladder-sparing treatment, 2 additional cycles of tislelizumab were performed. Bladder-sparing rate was settled as the exploratory endpoint based on 2-years of follow-up and predictive biomarker will be analyzed.
Results
To date, 21 of 30 pts have been enrolled and 17 pts have completed the regimen. 2pts were excluded because of complicating with other disease (cerebral infraction or rectal cancer), and 2pts voluntarily quit due to intolerance of chemotherapeutic adverse effect (fatigue and gastrointestinal symptoms). 2pts showed partial response to the therapy and received RC after disease progression. 1pt have no response to the therapy and received palliative care as unsuitable for surgery. The remaining 10 of 17 pts successfully preserved their bladder by achieving pT0 (58.8%) after treatment. Among them, 3 pts have been followed up over 1 year and no relapse was observed.
Conclusions
These data support neoadjuvant chemotherapy plus immunotherapy as a feasible bladder-sparing choice for MIBC patients. Further completed follow-up data and biomarker analysis will accurately identify patients who are suitable for this therapy.
Clinical trial identification
ChiCTR2100050763.
Legal entity responsible for the study
The author.
Funding
Has not received any funding.
Disclosure
The author has declared no conflicts of interest.
Resources from the same session
137P - First-in-human results from a Phase I dose-escalation study of VSV-GP (BI 1831169) in patients with advanced solid tumors
Presenter: Stephane Champiat
Session: Poster Display
138P - Generation of frameshift mutated TGF_R2-specific T cells in healthy subjects following administration with cancer vaccine candidate FMPV-1/GM-CSF
Presenter: Else Inderberg
Session: Poster Display
139P - Safety and clinical activity of a novel anti-CCR8 antibody (LM-108) as a single agent or in combination with pembrolizumab in patients with advanced solid tumors: Results of phase 1 study
Presenter: Alexander Starodub
Session: Poster Display
140P - Eliciting mAbs targeting MHC-bound peptides with a novel antibody discovery platform
Presenter: Elli Sandberg
Session: Poster Display
141P - An IgE antibody targeting the melanoma-associated Chondroitin Sulfate Proteoglycan 4
Presenter: Lais Cristina Palhares
Session: Poster Display
142P - Identifying novel immunotherapy targets using machine learning and ex vivo validation
Presenter: Marcellus Augustine
Session: Poster Display
143P - Advancing Cancer Immunotherapy via HLA-G Pathway Modulation with UCB4594
Presenter: Ann WHITE
Session: Poster Display
144P - Discovery of CBO421, a first-in-class Drug Fc-Conjugate (DFC), targeting CD73 in Cancer
Presenter: Simon Döhrmann
Session: Poster Display
145P - An Engineered Ligand-Trap Biologic Targeting the CD47 Signaling Pathway for Cancer Treatment with Superb Efficacy and Safety Profiles
Presenter: ZONG SEAN JUO
Session: Poster Display
146P - A Novel Allosteric Oral Immunotherapy Small Molecule Modulates Adenosine 2A Receptor Signaling and Restores Anti-Tumor Immune Responses
Presenter: David Pejoski
Session: Poster Display